These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17311025)

  • 1. hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.
    Nutt JE; Foster PA; Mellon JK; Lunec J
    Br J Cancer; 2007 Mar; 96(5):762-8. PubMed ID: 17311025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
    Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
    Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib-related gene signature in bladder cancer cells identified by a cDNA microarray.
    Inoue R; Matsuyama H; Yano S; Yamamoto Y; Iizuka N; Naito K
    Anticancer Res; 2006; 26(6B):4195-202. PubMed ID: 17201133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
    Munk M; Memon AA; Nexo E; Sorensen BS
    BJU Int; 2007 Jan; 99(1):196-201. PubMed ID: 17092291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
    Lu Y; Liu P; Van den Bergh F; Zellmer V; James M; Wen W; Grubbs CJ; Lubet RA; You M
    Cancer Prev Res (Phila); 2012 Feb; 5(2):248-59. PubMed ID: 21982874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
    Taguchi T; Tsukuda M; Imagawa-Ishiguro Y; Kato Y; Sano D
    Oncol Rep; 2008 Jan; 19(1):65-71. PubMed ID: 18097577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
    Nutt JE; Lazarowicz HP; Mellon JK; Lunec J
    Br J Cancer; 2004 Apr; 90(8):1679-85. PubMed ID: 15083203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
    Lin HQ; Katsifis A; Meriaty H
    Anticancer Res; 2010 Dec; 30(12):4899-905. PubMed ID: 21187468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
    Memon AA; Sorensen SB; Nexo E
    Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.
    Ornskov D; Nexo E; Sorensen BS
    FEBS J; 2006 Dec; 273(23):5479-89. PubMed ID: 17116246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
    Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
    Zheng Y; Izumi K; Yao JL; Miyamoto H
    Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.